NCT06245824View on ClinicalTrials.gov

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

December 1, 2026

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan (T-DXd) with pyrotinib

T-DXd, 5.4mg/kg IV day 1 of a 21-day cycle. Pyrotinib, 400mg or 320mg, orally once a day, daily of a 21-day cycle.

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER